研究单位：[1]Hoffmann-La Roche[2]Peking University First Hospital,Beijing City,China,100034[3]Beijing You An Hospital[4]Digestive Dept,Beijing City,China,100069[5]Beijing Tsinghua Changgung Hospital,Beijing City,China,102218[6]Peking University People's Hospital,Beijing,China,100044[7]Hunan Cancer Hospital,Changsha CITY,China,410013[8]Sichuan Cancer Hospital,Chengdu City,China,610041[9]West China Hospital, Sichuan University[10]Surgical Oncology,Chengdu City,China,610041[11]The First Affiliated Hospital, Chongqing Medical University,Chongqing,China,400016[12]Southwest Hospital , Third Military Medical University,Chongqing,China,400038[13]The First Affiliated Hospital Of Fujian Medical University,Fuzhou City,China,350005[14]Mengchao Hepatobiliary Hospital Of Fujian Medical University,Fuzhou City,China,350025[15]The 900th Hospital of PLA joint service support force,Fuzhou,China,110016[16]Fujian Cancer Hospital,Fuzhou,China,350014[17]The First Affiliated Hospital of Sun Yat-sen University,Guangzhou City,China,510080[18]Sun Yet-sen University Cancer Center,Guangzhou City,China,510663[19]Nanfang Hospital, Southern Medical University,Guangzhou,China,510515[20]Harbin Medical University Cancer Hospital[21]internal medicine,Harbin City,China,150081[22]Anhui Provincial Hospital,Hefei,China,230001[23]Jiangsu Province Hospital (the First Affiliated Hospital With Nanjing Medical University),Nanjing City,China,210029[24]Jiangsu Cancer Hospital,Nanjing City,China,211100[25]Guangxi Cancer Hospital of Guangxi Medical University,Nanning,China,530021[26]The First Affiliate Hospital of Guangxi Medical University,Nanning,China,530021[27]Zhongshan Hospital Fudan Unvierstiy,Shanghai City,China,200032[28]Fudan University Shanghai Cancer Center,Shanghai City,China,200120[29]Renji Hospital Shanghai Jiaotong University School of Medicine,Shanghai City,China,200127[30]Shengjing Hospital of China Medical University,ShenYang,China,110004[31]Tianjin Cancer Hospital[32]Surgical Department,Tianjin City,China,300060[33]Hubei Cancer Hospital,Wuhan,China,430079[34]The First Affiliated Hospital of Xi''an Jiaotong University[35]Hepatobiliary surgery Department,Xi''an,China,710049[36]Xi''an Inernational Medical Center Hospital,Xi''an,China,710119[37]Zhejiang Cancer Hospital,Zhejiang,China,310022[38]Henan Cancer Hospital,Zhengzhou,China,450008[39]Zhuhai People''s Hospital,Zhuhai,China,519099[40]Aichi Cancer Center,Aichi,Japan,464-8681[41]Chiba University Hospital,Chiba,Japan,260-8677[42]Kurume University Hospital,Fukuoka,Japan,830-0011[43]Hiroshima University Hospital,Hiroshima,Japan,734-8551[44]Yokohama City University Medical Center,Kanagawa,Japan,232-0024[45]Kanagawa Cancer Center,Kanagawa,Japan,241-8515[46]Kitasato University Hospital,Kanagawa,Japan,252-0375[47]Osaka University Hospital,Osaka,Japan,565-0871[48]Kindai University Hospital,Osaka,Japan,589-8511[49]Toranomon Hospital,Tokyo,Japan,105-8470
研究目的：
This study will evaluate the efficacy and safety of atezolizumab plus bevacizumab combined with on-demand TACE compared to on-demand TACE alone in participants with hepatocellular carcinoma who are unsuitable for curative therapy.
